As a global leader in custom mAb generation, GenScript’s MonoRab™ technology is able to generate a large number of high-quality rabbit mAbs to maximize the success of identifying mAbs perfect for your specific research application(s). Our advanced, proprietary rabbit mAb discovery technology involves the isolation and cloning of rabbit B cells, and capitalizes on the rabbit’s natural ability to generate high-specificity, high-affinity mAbs towards a wide range of difficult targets such as small molecules, Ab drugs, and even antigens that are non-immunogenic in mice.
Identify the top mAbs for your application by testing them in-house!
High clone number delivery & industry-leading turnaround times!
Dedicated Ph.D.-level project managers & 24 h technical support
MonoRab™ is a full-scale, comprehensive antibody generation service which harnesses GenScript’s advanced expertise in rabbit mAb discovery. With our proprietary immunization and B cell cloning technologies, we are able to generate a large number of diverse, high-affinity rabbit mAbs towards your target antigen with industry-leading turnaround times and highly competitive pricing.
In addition to customizing a MonoRab™ package tailored specifically to your needs, we also offer comprehensive antigen design and production services.
|I) Animal Immunization||4 rabbits (express or conventional immunization)||Express: 5 - 6 weeks Conventional: 8 - 10 weeks||• Antiserum report
• Small scale pAb purification (optional)
|II) B Cell Cloning and Screening||1 round of B cell cloning||3 weeks||• Positive clones report
• 1 ml B cell supernatant delivery, up to 50 clones (optional)
Additional screening and increased clone number delivery options available
|III) Antibody Sequencing & Small Scale Transfection||Sequencing of 5 customer-selected clones, followed by small scale rAb expression||3 weeks||• Sequence reports
• Up to 5 rAb supernatants (2 ml), or purified rAb (0.1 mg)
Additional sequencing and supernatant delivery options available
|IV) Recombinant Antibody Production||Scalable expression of selected recombinant rabbit mAbs||3 weeks||• Sequencing report
• Purified antibody
Due to the rabbits superior immune system, they can generate antibodies with higher specificity, sensitivity, affinity, and diversity than those generated in more commonly used model species.
Non-rabbit mAbs often fail to detect difficult antigens (Ags) such as small molecules, Ags with highly similar epitopes, post-transcriptionally-modified Ags, and Ags with no immunogenicity in mice. They also tend to require stringent optimization protocols in order to work in certain applications, possibly affecting the overall effectiveness of the experiment and interpretation of the results.
In Vitro Diagnostics: A variety of In Vitro diagnostic (IVD) assays, such as IHC, ELISA, and radio immunoassays (RI) are based on the principles of antigen-antibody binding. Given the critical role these assays play in patient and animal care, it is extremely important that IVD assays are carried out using the highest sensitivity and affinity mAbs available.
In Vivo Imaging: Visualization of mAbs can be accomplished through numerous means; however, the most common method is through labelling of mAbs with radioactive or fluorescent molecules to help track them in the body and aid in quantifying the results.
In Vitro Diagnostics (IVD)
In Vivo Imaging
Anti-Idiotype Antibodies: Pharmacokinetic (PK) assays are used to measure the absorption and excretion rates, distribution, and half-life of candidate small molecules or mAb therapeutics. Results from these assays help identify the optimal dose and toxicity risks of a therapeutic molecule. Therefore anti-idiotype antibodies need to be sensitive enough to capture trace amounts of their antibody target in free, bound, and total forms in biological fluid samples.
mAb therapeutics: The high specificity and sensitivity of an antibody towards its target antigen reduces both safety and toxicity concerns: highly specific antibodies avoid off-target binding and hence, offer safety; highly sensitive antibodies require low dosage administration and hence, cause a minimum level of toxicity.
CAR-T mAb Based Therapeutic
Introducing the latest cutting edge developments to the MonoRab™ rabbit mAb generation platform
Feature in "The Scientist"
Introduction to GenScript's Premier Rabbit mAb Generation platform
Rabbit Monoclonal Antibodies in Tissue Diagnostics
SARS-CoV-2 ECD rabbit mAbs display high affinity.
Epitope binning data additionally shows high rabbit mAb diversity.
To purchase these mAbs, please click here for more information.
A The cross reactivity rate of GenScript produced anti-Ractopamine (small molecule) rabbit mAb is 0.0304%, showing low cross reactivity rates with similar compounds.
B GenScript produced anti-idiotype rabbit mAb 90G12F8 binds with Pembrolizumab (mAb drug) with an EC50 of 5.001 ng/ml as shown via ELISA.
C Genscript produced N-Terminal anti-flag-tag rabbit (section 1) mAb shows higher specificity and affinity than those produced in mouse (section 2) as shown via western blot.
D GenScript produced anti-idiotype rabbit mAb 90G12F8 has a KD valu e of 2.3x10 -12 M against the antibody drug (Pembrolizumab) as shown via ELISA.